Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025 -0.3% 8.375 8.25 8.50 8.45 8.375 8.40 928,922 15:01:43
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 5.7 0.2 0.1 167.5 37

Byotrol Share Discussion Threads

Showing 7726 to 7748 of 10375 messages
Chat Pages: Latest  319  318  317  316  315  314  313  312  311  310  309  308  Older
DateSubjectAuthorDiscuss
04/2/2020
20:33
Why weren't commercial partners scrambling to partner with Byot like they did last time ? Why did some partners who did, give up, eg Tesco? Byot said in May last year that they were CLOSE to securing a 2nd retailer but now they are searching for a partner... Seems like that potential 2nd retailer pulled out, doesn't it? "We continue our search for a partner for Byotrol24 in the US and have engaged professional advice to assist. Sales at Target continue to increase year on year and month on month, but are not large enough to justify continued, national marketing spend by us even at very small levels. We are now preparing for the trial at Target to finish at the end of March 2020." https://uk.advfn.com/stock-market/london/byotrol-BYOT/share-news/Byotrol-PLC-Interim-Results/81386580 May 2019: "We are also now close to securing an additional new national retailer trial in the US." https://uk.advfn.com/stock-market/london/byotrol-BYOT/share-news/Byotrol-PLC-Trading-Update/79868900 TESCO: Question is whether they've managed to find alternative retailer, sign agreements and supplied them before the Coronavirus outbreak settles and is old news.. "Post year end we came to the end of our licence relationship with Robert McBride plc and therefore to supplying surface sprays to Tesco. This was an excellent arrangement for us for many years, but it has now run its course and we expect to generate higher margin opportunities with better brand equity from other consumer initiatives. " https://byotrolplc.com/wp-content/uploads/2019/10/Byotrol-Annual-Report-FY-2018-19.pdf
sikhthetech
04/2/2020
20:27
Did I forget to copyright that post stt? Do you not have any original thoughts or even phrasing? That was actually my farewell post (for the time being) on the tly thread. Can we hope that you will also copy the action as well as the words? htTps://uk.advfn.com/cmn/fbb/thread.php3?id=32815963&from=11298
1gw
04/2/2020
20:22
You have a number of posters on this thread who have been in for years, have been wrong for years, and have a huge vested interest in seeing the shareprice recover - and they are not shy at underplaying the risk, overplaying the potential, and playing dirty to try to discredit anyone who dares to present contrarian views and facts from the Company rns'. The ONLY way they can entice newbies in is targeting anyone with contrarian views or those posting facts from the company rns'. Wonder why???
sikhthetech
04/2/2020
17:13
If the trolls must keep reposting ...a great post by 1GWKeep up at the back, sikhthetech. Where do you think the funds to buy Medimark came from? As I understand it, Byotrol looked at recruiting their own sales staff but came to the conclusion that a better solution was to buy Medimark which came with proven sales & marketing expertise. As you will know from following the Totally plc / Greenbrook Healthcare story, acquisitions often take longer to bring to conclusion than you might think. The earn-out mechanism caused them to silo Medimark for [edit] over 1 year post-acquisition, which must have been frustrating, but perhaps better than what happened with Totally plc where it appears the company fell out with sellers of at least one business over measurement of earn-out, presumably because they integrated too quickly and didn't silo sufficiently.In terms of bigger picture timing, I think they've spent several years focusing mainly on the science and the regulation: getting formulae perfected and then getting formulae and labelling through the various regulatory bodies in the EU and the US. Not much good having a big sales and marketing team if you're still developing the product and labelling. I think the EU target may still be moving to some extent, but they're now in good shape on the regulatory side, especially in the US with receipt of the necessary approvals to allow them to launch byotrol 24 on a trial basis through Target.Ultimately I view byotrol as a technology company which happens to have an FMCG market, rather than as a wholesaler or retailer. As such it has historically focused on development of the product rather than on the sales and marketing, realising a lot of its "revenue" to this point through sales or licensing of its technology/product.The hope now, is that with product developed and sales & marketing in place, at least on the professional side, it can now ride a wave of industry change (regulatory-driven as older technologies, including possibly alcohol-based products, come under pressure). Companies such as SC Johnson (with whom byotrol have already agreed the licensing deal into the NHS), Purrell and lots of smaller ones may well be looking to license technology that already has the regulatory ticks.In the US they've taken a different approach, setting their sights on the consumer FMCG market with byotrol 24. They are not resourced to finance competitive sales and marketing on this by themselves and so are seeking an investment partner, armed with real consumer data from the extended Target trial.The coronavirus scare should, imo, give a boost to the prospects of finding a US investment partner on attractive terms. It may also open up the possibility of doing something similar with a hand sanitiser product in the US. It may push Solvay into accelerating whatever they have planned for Actizone (byotrol technology sold to Solvay, but with a retained royalty arrangement). Finally it may perhaps up their UK consumer profile, especially through the Boots deal where there is byotrol branding on the product - whether this is sufficient to justify a major push on UK consumer through either internal sales & marketing or seeking an investment partner here as well remains to be seen.With luck, byotrol may now be in the right place at the right time: newly approved technology and labelling (and various "non-core" technologies ready for out-licensing) just as other companies struggle to address a more restrictive regulatory environment. And on consumer, a product with some particular selling points which may just catch a vastly-increased coronavirus-inspired demand for anti-virals.Not that they don't deserve that luck in my opinion. The team under David Traynor has done exceptionally well to position the company here at this time, working within such a limited budget for many years. And at least on regulatory change, the company has been positioning for just such an outcome - you can read back through past reports to see that that is by design, not luck, although the Purrell news coinciding with the coronavirus scare is perhaps fortuitous in terms of increasing awareness of what byotrol has.
slicethepie
04/2/2020
17:04
According to their interims, published only a month ago, revenues from consumer segment were only £410k, inc a contribution from Tescos... so consumer revenues about £35k from non-Petcare for 6 months. Even a 10fold increase in consumer sales, ex Petcare, wouldn't add much revenue to Consumer division.... £350k over 6 months or £30k a month... What will happen once the Coronavirus is under control. "Headline H1 revenues in this segment were £0.41m versus £0.45m in H1 2018 (as restated). Petcare remains the largest element of day-to-day sales in consumer, accounting for 92% of consumer sales in the period." https://www.investegate.co.uk/byotrol-plc--byot-/rns/interim-results/201912190700053983X/
sikhthetech
04/2/2020
16:14
Kcowe, "as monday last week 1 purchased 100 .... in one order .".. really... 100 x 200ml bottles... ;-) Why would you need 100 bottles @ £5.19 (buy one get 1 1/2 price) ???
sikhthetech
04/2/2020
14:23
Still here ,early days yet .=. over bought at the moment , still out of the bolly bands .. will catch up in a couple of days . then onwards and upwards .
kcowe
04/2/2020
13:46
suddenly gone quiet here soon after the drop after 9.30am!!... I'm sure the p&d will return for another go...
sikhthetech
04/2/2020
09:24
Our mm hope not, happy to take a 10% spread on most buys and sells.
slicethepie
04/2/2020
08:58
Has the circus moved on then?
1gw
03/2/2020
18:45
Noticed this headline on CNBC's reporting of coronavirus. Puts things into perspective: "The flu has already killed 10,000 across US as world frets over coronavirus" And some backup stats from the CDC, including "between 12,000 – 61,000 deaths annually since 2010" hTtps://www.cdc.gov/flu/about/burden/index.html Still, if ever there was a favourable environment in which to close a funding deal for the full-scale commercial launch of byotrol24, I would have thought this has to be it.
1gw
03/2/2020
12:27
Bargain here still - miles to go
philjeans
03/2/2020
09:35
From the Independent :- "Scientists are hoping to develop a potential vaccine against the Chinese coronavirus within 16 weeks, ready for clinical trials that would last four months, writes health correspondent Shaun Lintern" Going to be a while before they find a vaccine...
saint in exile
03/2/2020
09:02
Adme has a crazy RNS why ever a few billions investment company will sign with them?
costax1654x
03/2/2020
08:45
Exactly as expected.. ;-) sikhthetech27 Jan '20 - 14:49 - 3973 of 4004 Edit 0 0 3 I bought some earlier...purely on the basis the Coronavirus will keep people interested and 1gw and his mates are pumping these.... Will look at selling before any TU... Obviously 1gw won't be selling ANY as he's confident of a major deal closing soon, will you 1gw??? ;-)
sikhthetech
03/2/2020
08:31
well, Smithie6 was singing the praises of this share all of last week... but no one was very interested. anyway, got yet another one right
smithie6
03/2/2020
08:30
Amazon sold out. Boots sold out.. Massive potential here. Chart very bullish. Was once 82p
letmepass
03/2/2020
08:30
3p showing as the highest ask and no reason not to get at least there today. f
fillipe
03/2/2020
08:28
Trading losses are reducing rapidly and will continue to do so as the formal integration with Medimark concludes at year end. The team is also working on a number of business development and monetisation opportunities that should improve results for the full year. The board remains confident that the Company is on target to deliver sustainable operating profits.We remain very excited about the business outlook for Byotrol."
letmepass
03/2/2020
08:17
According to their interims, published a month ago, revenues from consumer division were only £410k... about £35k from non-Petcare.. Even if they sell 10x H1 that's still only £350k.. What will happen once the Coronavirus is under control... "Headline H1 revenues in this segment were £0.41m versus £0.45m in H1 2018 (as restated). Petcare remains the largest element of day-to-day sales in consumer, accounting for 92% of consumer sales in the period." https://www.investegate.co.uk/byotrol-plc--byot-/rns/interim-results/201912190700053983X/
sikhthetech
03/2/2020
08:07
Struggling to top up on this. Keep getting nt
easwarareddy
03/2/2020
08:06
Right place - right time. And right price too! Going UP.
philjeans
03/2/2020
08:01
Are you talking about ncyt? That's a spike waiting to dive
easwarareddy
Chat Pages: Latest  319  318  317  316  315  314  313  312  311  310  309  308  Older
ADVFN Advertorial
Your Recent History
LSE
BYOT
Byotrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200922 02:02:11